Screener
Nuvectis Pharma, Inc. NVCT Business Segments — Net Income Loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Nuvectis Pharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 9:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-055318
| Line item | Three Months Ended March 31 / 2026 | Three Months Ended March 31 / 2025 |
|---|---|---|
| Research and development | $4,106 | $3,680 |
| General and administrative | 2,154 | 1,888 |
| OPERATING LOSS | (6,260) | (5,568) |
| Finance income | 210 | 236 |
| NET LOSS | $(6,050) | $(5,332) |
| TOTAL NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS | $(6,050) | $(5,332) |
| BASIC AND DILUTED NET LOSS PER COMMON SHARE OUTSTANDING, see Note 6 | $(0.26) | $(0.27) |
| Basic and diluted weighted average number of common shares outstanding | 23,414,475 | 19,937,507 |
Item 1. Financial Statements
FAQ
- What is Nuvectis Pharma, Inc.'s business segments — net income loss?
- Nuvectis Pharma, Inc. (NVCT) reported business segments — net income loss of -$6.05M in Q1 2026.
- How has Nuvectis Pharma, Inc.'s business segments — net income loss changed year-over-year?
- Nuvectis Pharma, Inc.'s business segments — net income loss decreased by 13.5% year-over-year, from -$5.33M to -$6.05M.
- What does business segments — net income loss mean?
- The bottom-line financial result for the clinical development segment, calculated as segment revenue minus segment-specific operating expenses. For early-stage biopharmaceutical companies, this typically represents the cash burn rate associated with R&D activities.
Ask your AI about Nuvectis Pharma, Inc.'s business segments — net income loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude